Enovis (ENOV) Income from Continuing Operations (2010 - 2026)
Enovis' (ENOV) quarterly Income from Continuing Operations came in at 8411000.0 in Q2 2026, up 84.87% year-on-year from 4549760.87 in Q2 2025, and up 98.38% on a QoQ basis from 518803000.0 in Q4 2025.
Enovis (ENOV) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Enovis (ENOV) has 17 years of Income from Continuing Operations data on file, last reported at 8411000.0 in Q2 2026.
- On a quarterly basis, Income from Continuing Operations rose 84.87% year-over-year to 8411000.0 in Q2 2026; TTM through Apr 2026 was 1134542000.0, a 39.87% decrease from a year earlier, with the FY2025 full-year figure at 1181711000.0, down 42.82% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 8411000.0, up from 518803000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ENOV reached as high as 120651000.0 in Q3 2022 and fell as low as 703626000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 124095000.0 across 5 years, with a median of 36455000.0 in 2025.
- Across the five-year window, Income from Continuing Operations soared 386.58% in 2022 and sank 23034.35% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 54840000.0 in 2022, then surged by 105.59% to 3068000.0 in 2023, then sank by 23034.35% to 703626000.0 in 2024, then gained by 26.27% to 518803000.0 in 2025, then jumped by 98.38% to 8411000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 8411000.0 in Q2 2026, 518803000.0 in Q4 2025, and 570873000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Enovis | 1.50 Bn | 1.47 Bn | 365.49 Mn | -8.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -8.41 Mn |
| Dec 31, 2025 | -518.80 Mn |
| Oct 3, 2025 | -570.87 Mn |
| Jul 4, 2025 | -36.46 Mn |
| Apr 4, 2025 | -55.58 Mn |
| Dec 31, 2024 | -703.63 Mn |
| Sep 27, 2024 | -33.51 Mn |
| Jun 28, 2024 | -18.44 Mn |
| Mar 29, 2024 | -71.84 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Sep 29, 2023 | -19.45 Mn |
| Jun 30, 2023 | -14.61 Mn |
| Mar 31, 2023 | -22.85 Mn |
| Dec 31, 2022 | -54.84 Mn |
| Sep 30, 2022 | -65.95 Mn |
| Jul 1, 2022 | 120.65 Mn |
| Apr 1, 2022 | -38.10 Mn |
| Dec 31, 2021 | -14.70 Mn |
| Oct 1, 2021 | -13.55 Mn |
| Jul 2, 2021 | -42.10 Mn |